Aardvark Therapeutics (AARD) Stock Analysis: AI Score & Alternative Data
Aardvark Therapeutics — alt-data steady across 90 days
Is Aardvark Therapeutics a buy right now? The alternative data says hold. This AARD stock analysis is built on the 25+ alternative data signals AltIndex tracks on Aardvark Therapeutics every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 44/100: a Hold. The stock trades at $4.76 with a $104M market cap.
No core signal has moved more than 5% in 90 days — steady, but without the momentum that pushes a stock into buy territory.
AARD’s broader alt-data profile also covers headcount (31 employees, according to LinkedIn), web traffic (4K monthly visits), Instagram followers (200), and sentiment (100/100). Every signal links to its own page with full history, the AARD technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on AARD is just below.
Aardvark Therapeutics AI Stock Analysis
Aardvark Therapeutics is a prominent player in the biotechnology sector, focusing on innovative therapeutic solutions. The company has made significant strides in the development of novel drugs and treatments, particularly in niche markets where there is a high unmet medical need.
Analysis generated September 28, 2026.
Recent Aardvark Therapeutics Stock Alerts
|
Aardvark Therapeutics | October 6 Price is down by -6.5% in the last 24h. |
|
Aardvark Therapeutics | October 5 Price is up by 6.9% in the last 24h. |
|
Aardvark Therapeutics | October 2 Price is down by -6.6% in the last 24h. |
|
Aardvark Therapeutics | September 25 Price is down by -7.4% in the last 24h. |
Aardvark Therapeutics Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 4K | N/A | |
| Job Posts | 0 | N/A | |
| LinkedIn Employees | 31 | N/A | |
| Sentiment | 100 | 0% | |
| Reddit Mentions | 0 | N/A | |
| X Mentions | 1 | N/A | |
| Stocktwits Mentions | 0 | 100.0% | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 142 | N/A | |
| Instagram Followers | 200 | N/A | |
| Facebook Followers | 43 | N/A | |
| Facebook Engagement | 0 | N/A |
About Aardvark Therapeutics (AARD)
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. The company is headquartered in San Diego, California.
| Price | $4.76 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $104M |
| Year Range | $3 – $16 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Aardvark Therapeutics News
View more →
Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitOctober 9 - PRNewswire |
|
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS LawOctober 8 - PRNewswire |
|
 |
AARDVARK THERAPEUTICS (NASDAQ: AARD) SECURITIES CLASS ACTION: ROSEN, A TOP RANKED LAW FIRM, Encourages Investors with Losses in Excess of $100K to Secure Counsel Before Important October 13 DeadlineOctober 7 - PRNewswire |
 |
AARD 6-DAY DEADLINE ALERT: Aardvark Therapeutics Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before October 13, 2026 Lead Plaintiff DeadlineOctober 7 - PRNewswire |
See Aardvark Therapeutics’s complete price and AI Score history
Sign up to unlock 1-year and all-time charts for AARD, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREEAardvark Therapeutics Earnings & Financial Performance
View all earnings →Aardvark Therapeutics Insider Trading Activity
View all →| Sun Nelson filed to sell 35,475 shares at $0.0. Sep 11 '26 |
| Sun Nelson filed to sell 97,475 shares at $0.0. Sep 10 '26 |
| Lee Tien-Li filed to sell 1,551,613 shares at $0.0. Dec 11 '25 |
| Sun Nelson filed to sell 108,484 shares at $0.0. Dec 11 '25 |
| Lee Tien-Li filed to sell 1,543,384 shares at $0.0. Sep 15 '25 |
Aardvark Therapeutics Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Aardvark Therapeutics
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
Black Diamond TherapeuticsBDTX |
$1.83 1.1% | $104M | 36 |
 |
Biomea FusionBMEA |
$1.42 3.7% | $103M | 47 |
 |
Coeptis TherapeuticsCOEP |
$16.40 1.2% | $102M | 45 |
 |
PDS BiotechnologyPDSB |
$1.38 35.3% | $100M | 66 |
 |
Rani Therapeutics HldgsRANI |
$0.80 0.9% | $111M | 49 |
Explore Aardvark Therapeutics Data
Frequently Asked Questions: Aardvark Therapeutics (AARD)
Aardvark Therapeutics has an AltIndex AI Score of 44/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
44/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Aardvark Therapeutics (AARD) stock is $4.76 with a market cap of $104M.
As of today, Aardvark Therapeutics’s PE (Price to Earnings) ratio is —.
View the latest Aardvark Therapeutics insider transactions to see recent buying and selling activity by company executives and directors.
Check the Aardvark Therapeutics congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The AARD stock price chart above shows Aardvark Therapeutics’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Aardvark Therapeutics technical analysis for RSI, moving averages, and more.
See the stocks similar to Aardvark Therapeutics section on this page for companies in the same industry ranked by market cap and AI Score.
